此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

鼻内催产素治疗苯二氮卓戒断的效果:一项试点随机对照试验

2026年9月23日 更新者:St. Olavs Hospital

Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot Randomized Parallel Group Placebo-Controlled Trial

The goal of this clinical trial is to learn if oxytocin administered as a nasal spray will reduce withdrawal symptoms in adults during benzodiazepine tapering for 21 days. It will also learn about the safety of oxytocin. The main questions it aims to answer are:

Does oxytocin reduce benzodiazepine withdrawal symptoms and make it easier to succeed tapering? Does oxytocin help reduce sleep difficulties and anxiety or restlessness during benzodiazepine tapering? Does oxytocin help reduce benzodiazepine craving?

We will compare oxytocin nasal spray to a placebo nasal spray containing regular saline to see if oxytocin works accordingly.

Participants will:

Take oxytocin or a placebo nasal spray, three times daily for 21 days during inpatient benzodiazepine tapering.

Fill out an online questionnaire every day and keep a record of their symptoms.

研究概览

详细说明

Background Benzodiazepine withdrawal can be challenging, often accompanied by severe anxiety, insomnia, and other withdrawal symptoms. Recent studies suggest that intranasal oxytocin (OT) may have anxiolytic properties and could potentially ease withdrawal symptoms. This study aims to evaluate the efficacy and safety of intranasal OT in the treatment of benzodiazepine withdrawal.

Objectives The primary objective is to evaluate if intranasal OT can reduce withdrawal symptoms in patients during benzodiazepine tapering. Secondary objectives include evaluating the safety and tolerability of intranasal OT and its impact on anxiety levels and sleep quality.

Methods

  • Design: This is a randomized, parallel-group, placebo-controlled trial.
  • Participants: Adults (aged 18-65) undergoing inpatient benzodiazepine tapering.
  • Intervention: Participants were randomly assigned to receive either intranasal OT (16 IU per administration, given three times daily, for a total daily dose of 48 IU) or placebo for 21 days during inpatient benzodiazepine tapering.
  • Assessments: Withdrawal symptoms were measured using the Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) scale. Anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), and sleep was measured using the Insomnia Severity Index (ISI), actigraphy, and Somnofy.

Procedure

  1. Screening: Eligible participants underwent a screening process, including medical history, physical examination, and baseline assessments.
  2. Randomization: Participants were randomly assigned to the OT or placebo group.
  3. Treatment Phase: Participants self-administered the nasal spray three times daily for three weeks. Participants filled out daily questionnaires to monitor symptoms and side effects. Urine samples for toxicology were collected twice weekly during the intervention period, and blood samples were collected at screening and at the end of the intervention period.
  4. Post-Treatment Follow-Up: Participants were assessed at the end of the treatment period and again four and twelve weeks post-treatment to evaluate the persistence of effects.

Expected Outcomes It was hypothesized that participants receiving intranasal OT would experience a significant reduction in withdrawal symptoms compared to the placebo group. Improvements in anxiety levels and sleep quality were also anticipated.

Significance This study could provide preliminary evidence for the use of intranasal OT as a supportive treatment for benzodiazepine withdrawal, potentially improving patient outcomes and comfort during the tapering process.

研究类型

介入性

注册 (实际的)

66

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Trøndelag
      • Trondheim、Trøndelag、挪威、7091
        • Blue Cross, Clinic Lade

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients aged 18 - 65 years, taking benzodiazepines at a daily dose of 20-80 mg diazepam-equivalent, and requiring inpatient benzodiazepine withdrawal. Included patients must consent to participate in the study.

Exclusion Criteria:

  • Female patients will be excluded if they are pregnant or are planning to become so, or if they are breast-feeding. Individuals incapable of completing questionnaires or giving informed consent will be excluded. Patients with concurrent acute medical or psychiatric illness requiring acute care hospitalization, misuse or dependency of alcohol or pregabalin/gabapentin will be excluded.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Participants in the placebo arm will receive a saline solution. Saline is an inert substance, meaning it has no therapeutic effect, making it an ideal placebo. The saline solution will be administered in the same manner as the experimental treatment. The treatment is administered intranasally. The treatment is blinded. Neither the participants nor the researchers know who is receiving the placebo and who is receiving the active treatment. Participants in the placebo arm will be monitored the same as those in the treatment arm. Participants will be fully informed about the possibility of receiving a placebo and will provide informed consent. The same outcome measures will be used for both the placebo and treatment arms.

Saline intranasal placebo comparator

实验性的:Oxytocin

Participants in this arm will receive intranasal oxytocin. The dosage and administration schedule will be consistent with the study protocol. Participants will receive 48 international units (IU) of oxytocin. The oxytocin will be administered intranasally using a nasal spray. Participants will insert the nasal spray container approximately 1 cm into each nostril and spray. They will wait 15 seconds before repeating administration until they have received a total of 4 puffs (2 in each nostril) per session thrice daily.

Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).

其他名称:
  • 催产素

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Benzodiazepine withdrawal symptoms
大体时间:21 days

Benzodiazepine withdrawal symptoms severity is measured with CIWA-B score, a 20-item scale where each item can be assigned a score from 0 to 4, i.e. the total score can range from 0 and 80 points. CIWA-B score will be measured daily from baseline (i.e. the day before the intervention starts) to day 21.

21 days

次要结果测量

结果测量
措施说明
大体时间
Benzodiazepine craving
大体时间:21 days

To test whether there is a difference between oxytocin and placebo on craving. Craving is measured daily with a Norwegian translation of the Brief Substance Craving Scale, adapted to benzodiazepines. Three items covering the intensity, frequency, and duration of craving during the past 24 hours are each scored from 0 to 4, giving a total score from 0 to 12. Higher scores indicate stronger craving, that is, a worse outcome. A fourth item records the number of craving episodes during the past 24 hours and is reported separately. The change in scores from baseline to day 21 is compared between the two study groups.

21 days
Benzodiazepine anxiety and depression symptoms
大体时间:21 days

To test whether there is a difference between oxytocin and placebo on rebound anxiety and depression symptoms. Symptoms are measured with the Hospital Anxiety and Depression Scale (HADS), a 14-item scale where each item is scored from 0 to 3, giving subscale scores from 0 to 21 for anxiety and for depression and a total score from 0 to 42. Higher scores indicate more severe symptoms, that is, a worse outcome. HADS is measured weekly from baseline to day 21, and the change in scores from baseline to day 21 is compared between the two groups.

21 days
Benzodiazepine sleep distress
大体时间:21 days

To test whether there is a difference between oxytocin and placebo on sleep. Sleep difficulties are measured with the Insomnia Severity Index (ISI), a 7-item scale where each item is scored from 0 to 4, giving a total score from 0 to 28. Higher scores indicate more severe insomnia, that is, a worse outcome. Sleep variables are also assessed by actigraphy and Somnofy. Scores are compared between the two study groups from baseline to day 21 during the intervention.

21 days
Benzodiazepine tapering "freezes"
大体时间:21 days

To test whether there is a difference between oxytocin and placebo in the number of "freezes" in diazepam tapering. A "freeze" (not reducing the diazepam dose as scheduled during tapering) will be noted for each subject and compared between the two study groups.

21 days

其他结果措施

结果测量
措施说明
大体时间
Follow-up: Relapse
大体时间:15 weeks

To test whether there is a difference between oxytocin and placebo in time to first benzodiazepine intake (up to 12 weeks after discharge). Comparing time (number of days) to first self-reported benzodiazepine intake after discharge (week 3) between the two study groups, by registration on the follow-up visits at week 7 and week 15.

15 weeks
Follow-up: Benzodiazepine withdrawal symptoms
大体时间:15 weeks

Difference between the oxytocin and placebo group in withdrawal symptoms measured with the Clinical Institute Withdrawal Assessment Scale for Benzodiazepines (CIWA-B) at week 7 and week 15 after discharge. CIWA-B is a 20-item scale where each item is scored from 0 to 4, giving a total score from 0 to 80. Higher scores indicate more severe withdrawal symptoms, that is, a worse outcome.

15 weeks
Follow-up: Benzodiazepine craving
大体时间:15 weeks

To test whether there is a difference between oxytocin and placebo on craving at week 7 and week 15 after discharge. Craving is measured with a Norwegian translation of the Brief Substance Craving Scale, adapted to benzodiazepines. Three items covering the intensity, frequency, and duration of craving during the past 24 hours are each scored from 0 to 4, giving a total score from 0 to 12. Higher scores indicate stronger craving, that is, a worse outcome. A fourth item records the number of craving episodes during the past 24 hours and is reported separately. Scores are compared between the two study groups.

15 weeks
Follow-up: Benzodiazepine anxiety and depression symptoms
大体时间:15 weeks

To test whether there is a difference between oxytocin and placebo on rebound anxiety and depression symptoms at week 7 and week 15 after discharge. Symptoms are measured with the Hospital Anxiety and Depression Scale (HADS), a 14-item scale where each item is scored from 0 to 3, giving subscale scores from 0 to 21 for anxiety and for depression and a total score from 0 to 42. Higher scores indicate more severe symptoms, that is, a worse outcome. Scores are compared between the two study groups.

15 weeks
Follow-up: Benzodiazepine sleep distress
大体时间:15 weeks

To test whether there is a difference between oxytocin and placebo on sleep distress at week 7 and week 15 after discharge. Sleep difficulties are measured with the Insomnia Severity Index (ISI), a 7-item scale where each item is scored from 0 to 4, giving a total score from 0 to 28. Higher scores indicate more severe insomnia, that is, a worse outcome. Scores are compared between the two study groups.

15 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Tone Aurora Pleym, MD, PhD-candidate、NTNU, Blue Cross, Clinic Lade, St. Olavs hospital
  • 首席研究员:Olav Spigset, MD, PhD、Department of Clinical Pharmacology, St. Olavs Hospital, and Norwegian University of Science and Technology (NTNU)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年3月1日

初级完成 (实际的)

2025年11月6日

研究完成 (实际的)

2026年1月29日

研究注册日期

首次提交

2024年10月17日

首先提交符合 QC 标准的

2025年1月2日

首次发布 (实际的)

2025年1月3日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅